HealthDay News – Patients with recent myocardial infarction have a lower risk for ischemic cardiovascular events with colchicine vs placebo, according to a study published online November 16 in the New England Journal of Medicine to coincide with the annual meeting of the American Heart Association, held from November 16 to 18 in Philadelphia.
Jean-Claude Tardif, MD, from the Montreal Heart Institute, and colleagues randomly assigned patients recruited within 30 days after myocardial infarction to either low-dose colchicine (0.5mg daily; 2366 patients) or placebo (2379 patients).
The researchers found that the primary efficacy end point (composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization) occurred in 5.5 and 7.1% of patients in the colchicine and placebo groups, respectively (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P =.02). For the components of the primary end point, the hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes; 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest; 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction; 0.26 (95% CI, 0.10 to 0.70) for stroke; and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization.
“A larger trial could have allowed a better assessment of individual end points and subgroups and the risks associated with colchicine,” the authors write.